Loading clinical trials...
Loading clinical trials...
For the management of low-density lipoprotein-cholesterol (LDL-C), some guidelines recommend initial statin treatment with high-intensity statins to achieve at least a 50% reduction in LDL-C levels. High-intensity or maximally tolerated intensity can be maintained without a target goal. However, the European guideline recommends less than 55 mg/dL of LDL-C after PCI.
To investigate the Optimal Attained LDL-C Levels in Patients Who Achieved ≥50% LDL-C Reduction After PCI.
Age
19 - No limit years
Sex
ALL
Healthy Volunteers
No
Samsung Medical Center
Seoul, South Korea
Start Date
January 1, 2024
Primary Completion Date
December 31, 2024
Completion Date
May 15, 2025
Last Updated
May 21, 2025
135,877
ACTUAL participants
LDL reduction therapy
DRUG
Lead Sponsor
Samsung Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07444697